<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="epcor-r-minicvp-shah">
    <meta name="study:title" content="PB3286 - Trial in progress: Epcoritamab with R-miniCVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma">
    <meta name="study:fileName" content="Abstracts/EPCORE-R-MINICVP.html">
    <meta name="study:cancerTypes" content="DLBCL,HGBCL,FL,LBCL,B-NHL"> <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Clinical trial"> <meta name="study:drugs" content="Epcoritamab,Rituximab,Bispecific antibodies,Monoclonal Antibody,Chemotherapy,CIT,R-miniCVP">

    <title>PB3286: Trial in progress: Epcoritamab + R-miniCVP for 1L DLBCL (Shah)</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> 
</head>
<body class="abstract-page-body"> 
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3286 - Epcoritamab + R-miniCVP in 1L DLBCL (Trial in Progress)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (Up to N=40)</h4>
                    <p>Newly diagnosed DLBCL, older/unfit or anthracycline-ineligible. Aim: Evaluate safety & efficacy of Epcor + R-miniCVP.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 64 64" fill="var(--sobi-teal)">
                        <path d="M32 60 V40 M20 40 L32 40 L44 40 M20 40 L12 28 L4 20 M44 40 L52 28 L60 20 M12 28 L16 24 M52 28 L48 24" stroke="var(--sobi-teal)" stroke-width="4" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
                        <circle cx="4" cy="20" r="3" fill="var(--sobi-orange)"/> <rect x="26" y="10" width="12" height="20" rx="2" stroke="var(--sobi-dark-blue)" stroke-width="2" fill="var(--sobi-light-teal-bg)"/> 
                    </svg>
                    <h4>Intervention</h4>
                    <p>Epcoritamab + R-miniCVP. Epcor step-up C2, then QW C2-3, Q3W C4-6. PRs continue Epcor Q4W to C12.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path fill-rule="evenodd" d="M2.25 2.25a.75.75 0 000 1.5H3v10.5a3 3 0 003 3h1.21l-2.12 2.121a.75.75 0 001.06 1.061l2.38-2.381a3.75 3.75 0 005.021 0l2.38 2.38a.75.75 0 101.06-1.06L14.79 18H16a3 3 0 003-3V3.75h.75a.75.75 0 000-1.5H2.25zm6.54 3.75a.75.75 0 01.04-.325l2.5-6.5a.75.75 0 011.42.55l-2.5 6.5a.75.75 0 01-1.46-.225z" clip-rule="evenodd" />
                    </svg>
                    <h4>Primary Endpoint</h4>
                    <p>CR rate after 6 cycles (Lugano criteria). Results pending.</p>
                </div>
                <div class="visual-abstract-item">
                   <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path d="M11.25 4.533A9.708 9.708 0 0012 4.5c1.518 0 2.94.355 4.225.982A.75.75 0 0117.25 6v1.533A9.708 9.708 0 0012 19.5a9.708 9.708 0 00-5.25-11.485V6a.75.75 0 011.025-.717A9.708 9.708 0 0012 4.5c-.34 0-.673.017-1 .05V1.5a.75.75 0 00-1.5 0v3.033z" />
                        <path d="M6.572 7.468A9.71 9.71 0 0112 19.5c1.518 0 2.94-.355 4.225-.982a.75.75 0 00-.5-1.432A8.21 8.21 0 0012 18c-1.317 0-2.572-.31-3.725-.852a.75.75 0 00-.702 1.368A9.71 9.71 0 0112 19.5c.34 0 .673-.017 1-.05V21a.75.75 0 01-1.5 0v-1.552A8.21 8.21 0 0112 18a8.21 8.21 0 01-3.725-.852.75.75 0 01-.702-1.368A9.71 9.71 0 0012 16.5c1.317 0 2.572.31 3.725.852A.75.75 0 0116.5 18v1.5a.75.75 0 001.5 0V18.05A9.71 9.71 0 0012 4.5c-1.518 0-2.94.355-4.225.982a.75.75 0 01.5 1.432A8.21 8.21 0 0012 6c1.317 0 2.572.31 3.725.852a.75.75 0 01.702-1.368A9.71 9.71 0 0012 4.5c-.34 0-.673.017-1 .05V3a.75.75 0 011.5 0v1.552A8.21 8.21 0 0112 6a8.21 8.21 0 013.725.852.75.75 0 00.702 1.368z" />
                    </svg>
                    <h4>Trial Status & Conclusion</h4>
                    <p>Phase 2 trial in progress (NCT06045247). Aims to assess safety & efficacy for older/unfit 1L DLBCL.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title uppercase">PB3286: TRIAL IN PROGRESS: EPCORITAMAB WITH R-MINICVP FOR OLDER UNFIT/FRAIL OR ANTHRACYCLINE-INELIGIBLE ADULT PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA</h1>
            <p class="abstract-sub-header">Rahul Shah, Ruitao Lin, Amanda Mason, Lauren Johnson, Jennifer Ramos, Gita Masand, Luis Malpica, Chijioke Nze, Preetesh Jain, Paolo Strati, Chris Flowers, Jason Westin, Dai Chihara</p>
            <p class="abstract-meta-info mt-2">EHA Library PB3286 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
        </div>

        <div class="grid md:grid-cols-12 gap-x-8 gap-y-6">
            <div class="md:col-span-8">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                        <li>Diffuse large B‑cell lymphoma (DLBCL) is the most common lymphoma worldwide, with a median age of diagnosis of around 65 years and a third of patients diagnosed at ≥75 years.</li>
                        <li>Older patients, particularly those who are unfit or frail or have contraindications to full dose anthracycline‑based chemoimmunotherapy, experience suboptimal outcomes with standard frontline treatment.</li>
                        <li>While R‑miniCHOP is the current standard for patients aged ≥80 years, its CR rate of 62% and 2‑year PFS of only 47% underscore the unmet need for a better tolerable and more effective therapeutic approach.</li>
                        <li>CD3xCD20 bispecific antibodies have shown efficacy and tolerability in therapeutic strategies for both frontline and relapsed/refractory DLBCL.</li>
                        <li>Hypothesis: Epcoritamab + R‑miniCVP will achieve CR rates comparable to R‑miniCHOP while maintaining safety in older/unfit patients and those with compromised cardiac function.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm">This phase 2 clinical trial aims to evaluate the safety and efficacy of epcoritamab in combination with R-miniCVP in patients with newly diagnosed stage DLBCL who are not eligible for full dose anthracycline-based chemoimmunotherapy.</p>
                </div>
                
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                        <li>Open‑label, single‑arm phase 2 clinical trial (NCT06045247) enrolling up to forty adult patients.</li>
                        <li><strong>Eligibility criteria include:</strong>
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>Age ≥ 18 years</li>
                                <li>ECOG PS 0-2</li>
                                <li>Newly diagnosed, histologically confirmed stage I-IV DLBCL (NOS, HGBCL, TCRBCL, Transformed Indolent Lymphoma)</li>
                                <li>Unable to receive standard full dose anthracycline-based chemoimmunotherapy due to:
                                    <ul class="list-disc list-inside ml-6 mt-1">
                                        <li>Age ≥80 years</li>
                                        <li>Unfit/frail status per simplified geriatric assessment criteria</li>
                                        <li>Reduced cardiac function (ejection fraction &lt;50% but ≥30%)</li>
                                        <li>Prior cardiotoxic cancer treatment with anthracycline</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Epcoritamab + R-miniCVP Treatment Schema</h3>
                        <div class="schema-step">
                            <strong>Enrollment (Up to N=40)</strong>
                            <span>Newly Diagnosed DLBCL, Unfit/Frail or Anthracycline-Ineligible</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-step">
                            <strong>Cycle 1 (21-day)</strong>
                            <span>R-miniCVP:</span>
                            <span>Rituximab 375mg/m² IV D1</span>
                            <span>Cyclophosphamide 400mg/m² IV D1</span>
                            <span>Vincristine 1mg IV D1</span>
                            <span>Prednisone 40mg/m² PO D1-5</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-step">
                            <strong>Cycle 2 (21-day)</strong>
                            <span>R-miniCVP (as above)</span>
                            <span>+ Epcoritamab Step-up:</span>
                            <span>0.16mg SQ C2D1 (Priming)</span>
                            <span>0.8mg SQ C2D8</span>
                            <span>48mg SQ C2D15</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-step">
                            <strong>Cycle 3 (21-day)</strong>
                            <span>R-miniCVP (as above)</span>
                            <span>+ Epcoritamab 48mg SQ QW</span>
                        </div>
                        <div class="schema-assessment-points"><span>PET after Cycle 3</span></div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-step">
                            <strong>Cycles 4-6 (21-day)</strong>
                            <span>R-miniCVP (as above)</span>
                            <span>+ Epcoritamab 48mg SQ Q3W</span>
                        </div>
                        <div class="schema-assessment-points"><span>PET after Cycle 6</span></div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-step">
                           <strong>Post Cycle 6 Decision Point</strong>
                           <span>CR: Complete Tx & Surveillance</span>
                           <span>PR: Continue Epcoritamab</span>
                           <span>SD/PD: Off Study</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-step">
                            <strong>Cycles 7-12 (for PR pts)</strong>
                            <span>Epcoritamab 48mg SQ Q4W</span>
                        </div>
                         <div class="text-center mt-3 text-xs text-gray-600">Response evaluated by Lugano criteria.</div>
                    </div>
                </div>
            </div>

            <div class="md:col-span-4">
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Study Design Figure</h2>
                    <div class="zoomable-image-container">
                        <img src="Assets/image_56c68f.png" alt="Study Design Schema for Epcoritamab + R-miniCVP" class="zoomable-image w-full h-auto rounded-md border border-gray-300 shadow-sm">
                    </div>
                    <p class="text-xs text-center mt-2">Study Design Schema. Click image to enlarge.</p>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Endpoints</h2>
                    <p class="text-sm mb-1"><strong>Primary:</strong> CR rate after 6 cycles.</p>
                    <p class="text-sm mb-1"><strong>Secondary:</strong> Best overall response rate, duration of response, progression‑free survival, overall survival, and safety.</p>
                    <p class="text-sm"><strong>Correlative studies:</strong> Pretreatment tumor and T‑cell characteristics, kinetics of response via circulating cell‑free DNA, and patient-reported quality-of-life outcomes.</p>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Results</h2>
                    <p class="text-sm">This is a trial-in-progress. Efficacy and safety results are not yet available. Key endpoints are being evaluated.</p>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary/Conclusion</h2>
            <p class="text-sm">This phase 2 clinical trial will assess the safety and efficacy of epcoritamab with R-miniCVP for patients unable to receive full dose anthracycline-based chemoimmunotherapy for newly diagnosed DLBCL.</p>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>
                1L, First-line; Ab, Antibody; ADC, Antibody-Drug Conjugate; AE, Adverse Event; C, Cycle (or Cyclophosphamide in R-CHOP/CVP); CAR-T, Chimeric Antigen Receptor T-cell; CD, Cluster of Differentiation; CIT, Chemoimmunotherapy; CR, Complete Response; CRR, Complete Response Rate; CRS, Cytokine Release Syndrome; CVP, Cyclophosphamide, Vincristine, Prednisone; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; Epcor, Epcoritamab; EOT, End of Treatment; FL, Follicular Lymphoma; G, Grade; H, Doxorubicin (Hydroxydaunorubicin) in R-CHOP; HGBCL, High-Grade B-Cell Lymphoma; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; IPI, International Prognostic Index; IV, Intravenous; LBCL, Large B-Cell Lymphoma; miniCVP, reduced dose CVP; miniCHOP, reduced dose CHOP; mos, months; NCT, National Clinical Trial; NOS, Not Otherwise Specified; O, Vincristine (Oncovin) in R-CHOP; ORR, Overall Response Rate; OS, Overall Survival; P, Prednisone/Prednisolone; PD, Progressive Disease; PET-CT, Positron Emission Tomography-Computed Tomography; PFS, Progression-Free Survival; PK, Pharmacokinetics; PO, Per Os (by mouth); PR, Partial Response; Pts, Patients; QW, Once Weekly; Q3W, Every 3 Weeks; Q4W, Every 4 Weeks; R, Rituximab; R/R, Relapsed/Refractory; SAE, Serious Adverse Event; SD, Stable Disease; SG, Simplified Geriatric; SOC, Standard of Care; SQ, Subcutaneous; TCRBCL, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; TEAE, Treatment-Emergent Adverse Event; TTR, Time to Response; TTCR, Time to Complete Response; Tx, Treatment; V, Vincristine in R-miniCVP.
            </p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-4 h-4 mr-1.5">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Shah R, Lin R, Mason A, et al. Trial in progress: Epcoritamab with R-miniCVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma. Abstract #PB3286 presented at European Haematology Association (EHA) June 12–15, 2025.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>NCT06045247 | EHA Library PB3286 | Presentation Date: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script> 
</body>
</html>
